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Cyclosporine Trough Concentration Monitoring 
in Liver Transplant Patients 
G.J. Burckart, R.J. Ptachcinski, R. Venkataramanan, S. Iwatsuki, C. Esquivel, 
D.H. Van Thiel, and T.E. Starzl 
CYCLOSPORINE A (esA) monitoring of blood or plasma concentration measure-
ments is recognized as an important part of 
the care of a transplant patient receiving the 
drug. The quantitation of CsA in biological 
fluids is essential for several reasons: (I) wide 
variability in the amount of CsA absorbed and 
the clearance rate of esA have been observed, 
particularly in orthotopic liver transplant 
(OLT) patients l ; (2) low CsA concentrations 
in blood or plasma secondary to poor drug 
absorption or rapid CsA elimination can be 
detected and adjusted; these situations are 
common in OL T patients due to diversion of 
bile through a T-tube and due to the occa-
sional need for anticonvulsant administration; 
(3) high blood or plasma concentrations of 
CsA can be avoided through routine monitor-
ing programs; these high levels may occur in 
OLT patients secondary to time-dependent 
increases in CsA absorption or to clamping of 
the T-tube; drugs that inhibit CsA metabo-
lism such as erythromycin2 also can compli-
cate therapy in OLT patients; (4) blood or 
plasma concentration monitoring aids adjust-
ment of CsA dosage during the transition 
from intravenous (IV) to oral therapy and 
from a high initial oral dose to a lower long-
term maintenance CsA dose; and (5) patient 
'compliance with the medication regimen can 
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be followed by blood or plasma esA measure. 
ment. 
CsA can be measured in whole blood or in 
plasma and serum samples. Important ditTer. 
ences exist among the sample matrices and 
have been discussed previously.! The interpre. 
tation of assay results from the two analytical 
methodologies available, high-performance 
liquid chromatography (HPLC) and the: 
radioimmunoassay (RIA), is particularly crit. 
ical in OLT patients. This article therefore 
discusses the appropriate timing of a trough 
sample and outlines those factors that affect 
the RIA and HPLC results in OL T patients. 
SAMPLE TIMING 
The trough concentrations of CsA should 
be that time at which the blood or plasma 
concentration is lowest. A delay in the rise of 
CsA concentrations following oral ingestion 
occurs because of delayed gastric emptying, 
but concentrations in blood or plasma increase 
by I hour following an oral dose. In most 
institutions, trough levels are obtained for 
drug concentration determination within I 
hour prior to the drug dose. 
The dosing interval may determine how 
critical the timing of a trough CsA concentra-
tion should be. With terminal elimination 
half-lives ranging from 10.7 hours in renal 
transplant patients4 to 20.4 hours in patient~ 
with hepatic cirrhosis,5 small differences in 
sample timing will have little effect on the 
trough concentration if CsA absorption and 
distribution are complete. Therefore, no clini-
cally significant difference will occur in 
trough samples obtained I to 2 hours prior to a 
dose when the patient receives CsA as a 
once-daily dose. However, shorter dosing 
intervals of 8 or 12 hours may require more 
precise timing of trough esA samples. esA 
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concentrations in blood or plasma may not 
peak until eight hours after an oral dose,s and 
the absorption and distribution processes are 
frequ('ntly prolonged for up to 12 hours. The 
change in CsA concentrations in blood or 
plasma during the interval of 6 to 12 hours 
following an oral dose is rapid in comparison 
wilh the slow elimination half-life of the drug. 
Altering the timing of the trough sample by I 
to 2 hours in a patient on an 8- to 12-hour CsA 
dosing schedule can result in significantly 
different blood or plasma concentrations. For 
example, Fig 1 presents the blood concentra-
tions of CsA measured by RIA and HPLC 
following an oral dose in a transplant patient. 
The CsA blood concentrations measured by 
HPLC at eight hours (544 ng/mL) fall rap-
idly to the 12-hour concentration (127 ng/ 
mL). The blood concentrations in this same 
patient measured by RIA decreased from 
1,512 ng/mL to only 1,244 ng/mL, resulting 
in a significant change in the ratio of 
RIA:HPLC. Imprecise sampling of blood dur-
ing the CsA absorptive and distributive phases 
of this patient could result in differing trough 
concentrations and their interpretation. Be-
cause changes in gastrointestinal (G I) func-
lion, dose administered, or concurrent drug 
therapy influence the absorptive pattern of 
CsA, precise trough sampling timing in 
patients on 8- or 12-hour dosing schedules 
should improve the reproducibility and clini-
_ 1600 
~ 1400 r·~·" '" c - 1200 w z "-~ ii 1000 
0 
B;aoo 
0 
...J 
600 ~ /x"-.. x/"-.. u 
0 400 
0 ~x~-x-x 0 200 ...J m 
0 2 4 6 8 10 12 14 16 18 
TIME( hr) 
Fig 1. Blood cyclosporine concentrations vtime in a 
transplant patient following en orel drug dOle. Measure-
mentl are by HPlC (x) and RIA (0). 
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cal utility of blood or plasma monitoring for 
CsA. 
Transplant patients on multiple daily doses 
of CsA should have their trough blood or 
plasma concentration sampled at the same 
time each day. CsA clearance rates have a 
diurnal variation with a more rapid clearance 
rate during the nighttime hours.6 Predose 
trough concentrations increased 38% and 72% 
when eveninglmples were collected in com-
parison with morning samples in two OL T 
patients.' Individual patient and transplant 
center sample times should be standardized so 
that the center can develop its own consistent 
guidelines for acceptable desired CsA concen-
trations. Differences in the sampling time and 
the CsA dosing interval used may account for 
the minor variations in the desired CsA range 
noted between transplant centers (see Table 
1). 
Changing the CsA dosing interval without a 
change in total daily CsA dose can have a major 
effect on blood or plasma concentrations. In a 
small number of renal transplant patients who 
received the same daily CsA dose but had their 
dosing interval changed from every 24 to every 
12 to every 8 hours, average steady-state CsA 
blood concentrations increased from 497 to 800 
to 1,241 ng/mL, respectively.5 Dose-dependent 
changes in drug absorption or elimination must 
Table 1. Desired Trough Cyclosporine Concentrations 
From Major Transplant Cantarl 
Desired 
Cyclosporine 
Transplant Biological Concentrations 
Population Fluid Assay (ng/mL) 
Liver1 Whole blood HPlC 100-400 
Renal" . Whole blood HPlC 100-200 
Renal" Whole blood HPlC 150-300 
Renal, first month 10 Plasma RIA <500 
Renal, long-term 10 Plasma RIA <50-150 
Renal" Serum RIA 100-400 
Renal" Serum RIA 100-500 
Renal" Serum RIA 150-300 
Renal" Serum RIA 100-200 
Bone marrow" Serum RIA 100-250 
Heart" Plasma RIA 100-200 
HeartH Serum RIA 200-500 
liver'" Whole blood RIA 800-1000 
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be considered when interpreting trough CsA 
concentrations after a dose or dosing interval 
alteration. 
RIA:HPLC CONCENTRATIONS 
Concentrations obtained by RIA analysis 
are consistently higher than those obtained by 
HPLC due to the cross-reactivity of CsA 
metabolites with the antiserum used in the 
RIA kits. '9•2o The percentage of cross-reactiv-
ity of some of the metabolites tested ranges 
from 4% to 32%. The RIA:HPLC ratio of 
CsA concentrations in blood, plasma, and 
serum is highly variable'9,21,22 and depends on 
the patient's liver function, the time of blood 
sampling in reference to the time of drug 
administration, the absolute CsA concentra-
tion, and whether the patient is receiving 
other drugs that alter hepatic metabolizing 
enzyme function. 
Assay results from the RIA should be used 
with particular caution during periods of 
impaired hepatic function. In the first 2 weeks 
following liver transplantation, during liver 
rejection, or in the event of a technical failure 
(eg, hepatic artery thrombosis), the 
RIA:HPLC ratio is dramatically increased.23 
Table 2 presents examples of the peak RIA: 
HPLC ratios observed early in the postopera-
tive course of ten liver transplant patients. The 
ratio of trough concentrations measured by 
the two assays stabilized in the RIA:HPLC 
ratio of 1.7 to 4.2 if hepatic function was also 
improving. A similar observation has been 
., 
- Tible 2. Ratio of RIA:HPLC Trough Blood 
Concentrations In Ten Liver Transplant Patients 
E.tyP .... Stable 
Patient Ratio Postoperative Dey Ratio PostOl*ltive dey 
1 4.7 3 2.2 17 
2 . 4.8 6 2.0 9 
3 5.2 6 1.7 10 
4 10.0 4 3.0 13 
6 6.4 2 2.7 5 
6 4.7 2 2.1 13 
7 7.5 2 4.2 7 
8 3.3 2 1.7 5 
9 6.6 1 2.8 7 
10 B.2 6 2.4 9 
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made in two OLT patients by Blyden et al 24 
who also report a positive correlation betwe~n 
the total serum bilirubin concentration and 
the RIA:HPLC ratio. In an earlier report,21 
we also noted that significant increases in the 
RIA:HPLC ratio to greater than 10 in Ol T 
patients with rises in bilirubin were associated 
with rejection or a technical complication. 
Smaller increases in the RIA:HPLC ratio 
were occasionally associated with increases in 
liver enzymes without a change in bilirubin. 
Patients with severe liver disease have the 
ability to metabolize CsA as evidenced by 
their 0.8 to 4.8 mL/min/kg clearance rate~ 
but have a significant impairment in their 
ability to excrete CsA metabolites. CsA blood 
concentration v time data in a patient with 
liver disease as analyzed by RIA and HPLC 
are presented in Figure 2. The RIA:HPLC 
ratio changes over the dosing interval studied 
(from 1:1 to 1:4), and the pharmacokinetic 
parameters calculated are differentS depend-
ing on the analytical procedure used. 
The time of the trough blood sampling for 
CsA can significantly affect the RIA:HPLC 
ratio. In Fig I, sampling eight hours after the 
oral CsA dose would have yielded an 
RIA:HPLC ratio of 2.8, but sampling at 12 
hours following the dose would change the 
results and ratio to 9.8. This difference in the 
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Fig 3. Blood concentrations measured by RIA " 
HPLC in a single patient over one dosing interval. The 
lolid line represents a 1:1 HPLC:RIA ratio. 
RIA:HPLC ratio over a dosing interval is 
explained by two observations. First, higher 
concentrations of CsA measured by HPLC 
result in better agreement between the RIA 
and HPLC assays because the parent CsA 
compound then comprises the majority of 
substance measured by RIA. At lower CsA 
concentrations in blood or plasma, the RIA is 
more likely to overestimate CsA, resulting in a 
higher RIA:HPLC ratio (see Fig 3). Second, 
the elimination half-life measured by RIA is 
greater than the CsA elimination half-life 
measured by HPLC. Therefore, the fall in 
CsA concentration in blood or plasma during 
RIA 
ng/ml 
4 
HPLC 600 
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a dosing interval measured by RIA will not 
parallel the decline measured by HPLC. 
Other pharmacologic agents may affect the 
formation or elimination of CsA metabolites, 
thereby affecting the RIA:HPLC ratio. For 
example, previous reports2S•26 have shown that 
CsA concentrations measured by RIA 
increase when methylprednisolone is adminis-
tered concurrently with CsA. Our own obser-
vations in paC .lts receiving high-dose meth-
ylprednisolone have not demonstrated any dif-
ference in CsA clearance measured by HPLC 
when compared with a control period.27 When 
patient trough concentrations were monitored 
by RIA and HPLC, an increase in the 
RIA:HPLC ratio was observed coincident 
with the administration of pulse doses of 
methylprednisolone (Fig 4). Methylpredniso-
lone affects the metabolism of CsA by 
enhancing the production of metabolites that 
react with the RIA but that have little effect 
on HPLC measurements. The effect of other 
drugs on the RIA:HPLC ratio is unknown but 
should be carefully monitored when pharma-
cologic agents known to alter CsA blood or 
plasma concentrations are taken concurrently 
with CsA (see Table 3). 
The importance of alterations in the 
RIA:HPLC ratio will become clearer as the 
ng/ml 200 ~~!!!!!!!!!!!!!!!!!!!!!! 
Fig 4. The ratio of 
RIA:HPLC blood trough concen-
tretion measuremants in a 
transplant patient over time. 
Note the increase in the ratio in 
association with Solu-Medrol 
Imethylprednisolone) dOling. 
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Table 3. Drug Interactions With Cyclosporine That Alter Blood or Plasme Measurements 
Drug Mechanism Effect Observed 
Ketoconazole'·-30 Impairment of cyclosporine me-
tabolism 
Increased blood concentrations of cyclospo-
rine leading to nephrotoxicity 
Erythromycin" Impairment of cyclosporine me-
tabolism 
Increased blood concentrations of cyclospo-
rine 
Methylprednisolone (high-
dose)"·2e 
Not known Increased plasma and blood concentrations of 
cyclosporine as measured by RIA; un-
changed blood concentrations of cyclospo-
rine as measured by HPLC; significance un-
known 
Phenytoin32•n Induces cyclosporine metabolism Lowering of cyclosporine blood concentra-
tions with associated rejection of trans-
planted organs 
Rifampicin"'" Induces cyclosporine metabolism Lowering of cyclosporine blood concentra-
tions with associated rejection of tr __ 
planted organs 
Phenobarbitone'" Induces cyclosporina metabolism lowering of cyclosporine blood concentra-
tions with associated rejection of trans-
planted organs 
Sulphadimidine-trimethoprim 
(lV)37 
Not known 
immunologic and toxicologic elf ects of CsA 
metabolites are defined. At present, the 
metabolites of CsA are considered to have 
little pharmacologic activity.38 If this observa-
tion is true, RIA trough CsA measurements 
could be misleading during periods of hepatic 
dysfunction or when other agents, such as 
methylprednisolone. alter the RIA:HPLC 
ratio. Trough CsA concentrations measured 
by RIA have been associated with both the 
nephrotoxicity of CsA IS and the tremors that 
the drug can induce.2" The RIA can provide 
useful trough CsA measurements on OL T 
patients who have stable hepatic function but 
should be used in conjunction with HPLC 
during -tne immediate postoperative weeks, 
'. during periods of changing hepatic function, 
and when other pharmacologic agents are 
administered that could alter the metabolism 
ofCsA. 
SUMMARY 
Trough blood or plasma concentration mea-
surements of CsA must be carefully inter-
preted in OLT patients in relation to hepatic 
function. sample timing, assay specificity, and 
concurrent drug therapy. The RIA:HPLC 
Decrease in serum cyclosporine levels; signifi-
cance unknown 
ratio of blood or plasma measurements will 
vary with the patient's liver function, the time 
of blood sampling in reference to the time of 
drug administration, the absolute CsA con-
centration, and concurrent use of drugs that 
may alter the metabolism of CsA. The RIA 
assay should be used in conjunction with 
HPLC for trough blood or plasma measure-
ment during the first postoperative weeks, 
during periods of changing hepatic function, 
and during changing drug regimens. In the 
future, the specific measurement of active or 
toxic metabolites of CsA should improve 
trough CsA concentration monitoring in OL T 
patients. 
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